AbbVie Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
AbbVie Inc. (ABBV) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of $3.62 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-03
- AbbVie Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was $3.62B, a 284.27% increase year-over-year.
- AbbVie Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was $697.00M, a 45.93% decline year-over-year.
- AbbVie Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was $1.81B.
- AbbVie Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was $188.00M, a 87.98% decline year-over-year.
- AbbVie Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was $4.23B, a 1.24% decline from fiscal 2024.
- AbbVie Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was $4.29B, a 12.05% decline from fiscal 2023.
- AbbVie Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was $4.87B, a 58.86% decline from fiscal 2022.
- AbbVie Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was $11.85B, a 2.56% increase from fiscal 2021.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.62B 10-Q · filed 2026-08-03 | $4.31B 10-Q · filed 2026-08-03 | $6.13B derived: sum of 3 quarters · filed 2026-08-03 | $6.32B derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $697.00M 10-Q · filed 2026-05-08 | $2.51B derived: sum of 2 quarters · filed 2026-05-08 | $2.70B derived: sum of 3 quarters · filed 2026-05-08 | $3.64B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $1.81B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $2.00B derived: sum of 2 quarters · filed 2026-02-20 | $2.94B derived: sum of 3 quarters · filed 2026-08-03 | $4.23B 10-K · filed 2026-02-20 |
| 2025-09-30 | $188.00M 10-Q · filed 2025-11-04 | $1.13B derived: sum of 2 quarters · filed 2026-08-03 | $2.42B 10-Q · filed 2025-11-04 | $2.40B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $941.00M 10-Q · filed 2026-08-03 | $2.23B 10-Q · filed 2026-08-03 | $2.21B derived: sum of 3 quarters · filed 2026-08-03 | $3.77B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $1.29B 10-Q · filed 2026-05-08 | $1.27B derived: sum of 2 quarters · filed 2026-05-08 | $2.83B derived: sum of 3 quarters · filed 2026-05-08 | $4.20B derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$23.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.54B derived: sum of 2 quarters · filed 2026-02-20 | $2.91B derived: sum of 3 quarters · filed 2026-02-20 | $4.29B 10-K · filed 2026-02-20 |
| 2024-09-30 | $1.56B 10-Q · filed 2025-11-04 | $2.94B derived: sum of 2 quarters · filed 2025-11-04 | $4.31B 10-Q · filed 2025-11-04 | $5.13B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $1.37B 10-Q · filed 2025-08-04 | $2.75B 10-Q · filed 2025-08-04 | $3.57B derived: sum of 3 quarters · filed 2026-02-20 | $5.35B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $1.37B 10-Q · filed 2025-05-09 | $2.20B derived: sum of 2 quarters · filed 2026-02-20 | $3.98B derived: sum of 3 quarters · filed 2026-02-20 | $6.00B derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $824.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $2.60B derived: sum of 2 quarters · filed 2026-02-20 | $4.63B derived: sum of 3 quarters · filed 2026-02-20 | $4.87B 10-K · filed 2026-02-20 |
| 2023-09-30 | $1.78B 10-Q · filed 2024-11-04 | $3.81B derived: sum of 2 quarters · filed 2024-11-04 | $4.05B 10-Q · filed 2024-11-04 | $6.52B derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | $2.03B 10-Q · filed 2024-08-07 | $2.27B 10-Q · filed 2024-08-07 | $4.74B derived: sum of 3 quarters · filed 2025-02-14 | $8.69B derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $241.00M 10-Q · filed 2024-05-03 | $2.71B derived: sum of 2 quarters · filed 2025-02-14 | $6.67B derived: sum of 3 quarters · filed 2025-02-14 | $7.59B derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | $2.47B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $6.42B derived: sum of 2 quarters · filed 2025-02-14 | $7.35B derived: sum of 3 quarters · filed 2025-02-14 | $11.85B 10-K · filed 2025-02-14 |
| 2022-09-30 | $3.95B 10-Q · filed 2023-11-06 | $4.88B derived: sum of 2 quarters · filed 2023-11-06 | $9.37B 10-Q · filed 2023-11-06 | $13.42B derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $928.00M 10-Q · filed 2023-08-07 | $5.42B 10-Q · filed 2023-08-07 | $9.47B derived: sum of 3 quarters · filed 2024-02-20 | $12.65B derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $4.49B 10-Q · filed 2023-05-05 | $8.54B derived: sum of 2 quarters · filed 2024-02-20 | $11.72B derived: sum of 3 quarters · filed 2024-02-20 | $12.49B derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $4.04B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $7.22B derived: sum of 2 quarters · filed 2024-02-20 | $7.99B derived: sum of 3 quarters · filed 2024-02-20 | $11.55B 10-K · filed 2024-02-20 |
| 2021-09-30 | $3.18B 10-Q · filed 2022-11-04 | $3.95B derived: sum of 2 quarters · filed 2022-11-04 | $7.50B 10-Q · filed 2022-11-04 | $7.54B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $769.00M 10-Q · filed 2022-08-04 | $4.32B 10-Q · filed 2022-08-04 | $4.36B derived: sum of 3 quarters · filed 2023-02-17 | $6.67B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | $3.56B 10-Q · filed 2022-05-06 | $3.59B derived: sum of 2 quarters · filed 2023-02-17 | $5.91B derived: sum of 3 quarters · filed 2023-02-17 | $5.17B derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $38.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $2.35B derived: sum of 2 quarters · filed 2023-02-17 | $1.61B derived: sum of 3 quarters · filed 2023-02-17 | $4.62B 10-K · filed 2023-02-17 |
| 2020-09-30 | $2.31B 10-Q · filed 2021-11-02 | $1.57B derived: sum of 2 quarters · filed 2021-11-02 | $4.58B 10-Q · filed 2021-11-02 | $7.38B derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-06-30 | -$739.00M 10-Q · filed 2021-08-02 | $2.27B 10-Q · filed 2021-08-02 | $5.07B derived: sum of 3 quarters · filed 2022-02-18 | $6.96B derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-03-31 | $3.01B 10-Q · filed 2021-05-07 | $5.81B derived: sum of 2 quarters · filed 2022-02-18 | $7.70B derived: sum of 3 quarters · filed 2022-02-18 | $8.44B derived: sum of 4 quarters · filed 2022-02-18 |
| 2019-12-31 | $2.80B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $4.68B derived: sum of 2 quarters · filed 2022-02-18 | $5.43B derived: sum of 3 quarters · filed 2022-02-18 | $7.88B 10-K · filed 2022-02-18 |
| 2019-09-30 | $1.88B 10-Q · filed 2020-11-04 | $2.63B derived: sum of 2 quarters · filed 2020-11-04 | $5.08B 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $741.00M 10-Q · filed 2020-08-04 | $3.20B 10-Q · filed 2020-08-04 | ||
| 2018-12-31 | $5.69B 10-K · filed 2021-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |